H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)

September 25, 2026 6:49 AM

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $20.00 price target on Enanta Pharmaceuticals (NASDAQ: ENTA).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found